598 related articles for article (PubMed ID: 33905949)
1. Development of oncolytic viruses for cancer therapy.
Abd-Aziz N; Poh CL
Transl Res; 2021 Nov; 237():98-123. PubMed ID: 33905949
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
[TBL] [Abstract][Full Text] [Related]
3. Development of oncolytic virotherapy: from genetic modification to combination therapy.
Lan Q; Xia S; Wang Q; Xu W; Huang H; Jiang S; Lu L
Front Med; 2020 Apr; 14(2):160-184. PubMed ID: 32146606
[TBL] [Abstract][Full Text] [Related]
4. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.
Chowaniec H; Ślubowska A; Mroczek M; Borowczyk M; Braszka M; Dworacki G; Dobosz P; Wichtowski M
Front Immunol; 2024; 15():1375433. PubMed ID: 38576614
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic Virotherapy.
Fatima M; Amraiz D; Navid MT
Cancer Treat Res; 2023; 185():105-126. PubMed ID: 37306907
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment.
Rosewell Shaw A; Suzuki M
Front Immunol; 2018; 9():2103. PubMed ID: 30298067
[TBL] [Abstract][Full Text] [Related]
7. The emerging field of oncolytic virus-based cancer immunotherapy.
Ma R; Li Z; Chiocca EA; Caligiuri MA; Yu J
Trends Cancer; 2023 Feb; 9(2):122-139. PubMed ID: 36402738
[TBL] [Abstract][Full Text] [Related]
8. Virotherapy in Germany-Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies.
Nettelbeck DM; Leber MF; Altomonte J; Angelova A; Beil J; Berchtold S; Delic M; Eberle J; Ehrhardt A; Engeland CE; Fechner H; Geletneky K; Goepfert K; Holm PS; Kochanek S; Kreppel F; Krutzke L; Kühnel F; Lang KS; Marchini A; Moehler M; Mühlebach MD; Naumann U; Nawroth R; Nüesch J; Rommelaere J; Lauer UM; Ungerechts G
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452286
[TBL] [Abstract][Full Text] [Related]
9. [Combination of Oncolytic Virotherapy and CAR T/NK Cell Therapy for the Treatment of Cancer].
Kochneva GV; Sivolobova GF; Tkacheva AV; Gorchakov AA; Kulemzin SV
Mol Biol (Mosk); 2020; 54(1):3-16. PubMed ID: 32163385
[TBL] [Abstract][Full Text] [Related]
10. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
Shi T; Song X; Wang Y; Liu F; Wei J
Front Immunol; 2020; 11():683. PubMed ID: 32411132
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.
Cervera-Carrascon V; Havunen R; Hemminki A
Expert Opin Biol Ther; 2019 May; 19(5):443-455. PubMed ID: 30905206
[TBL] [Abstract][Full Text] [Related]
12. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.
Rajani KR; Vile RG
Viruses; 2015 Nov; 7(11):5889-901. PubMed ID: 26580645
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy.
Rezaei R; Esmaeili Gouvarchin Ghaleh H; Farzanehpour M; Dorostkar R; Ranjbar R; Bolandian M; Mirzaei Nodooshan M; Ghorbani Alvanegh A
Cancer Gene Ther; 2022 Jun; 29(6):647-660. PubMed ID: 34158626
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic virotherapy: Challenges and solutions.
Goradel NH; Baker AT; Arashkia A; Ebrahimi N; Ghorghanlu S; Negahdari B
Curr Probl Cancer; 2021 Feb; 45(1):100639. PubMed ID: 32828575
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy.
Volovat SR; Scripcariu DV; Vasilache IA; Stolniceanu CR; Volovat C; Augustin IG; Volovat CC; Ostafe MR; Andreea-Voichița SG; Bejusca-Vieriu T; Lungulescu CV; Sur D; Boboc D
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256250
[TBL] [Abstract][Full Text] [Related]
16. Pouring petrol on the flames: Using oncolytic virotherapies to enhance tumour immunogenicity.
Teijeira Crespo A; Burnell S; Capitani L; Bayliss R; Moses E; Mason GH; Davies JA; Godkin AJ; Gallimore AM; Parker AL
Immunology; 2021 Aug; 163(4):389-398. PubMed ID: 33638871
[TBL] [Abstract][Full Text] [Related]
17. Poxvirus oncolytic virotherapy.
Torres-Domínguez LE; McFadden G
Expert Opin Biol Ther; 2019 Jun; 19(6):561-573. PubMed ID: 30919708
[TBL] [Abstract][Full Text] [Related]
18. Multidirectional Strategies for Targeted Delivery of Oncolytic Viruses by Tumor Infiltrating Immune Cells.
Osali A; Zhiani M; Ghaebi M; Meymanat M; Esmaeilzadeh A
Pharmacol Res; 2020 Nov; 161():105094. PubMed ID: 32795509
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic viruses in the treatment of cancer: a review of current strategies.
Zeyaullah M; Patro M; Ahmad I; Ibraheem K; Sultan P; Nehal M; Ali A
Pathol Oncol Res; 2012 Oct; 18(4):771-81. PubMed ID: 22714538
[TBL] [Abstract][Full Text] [Related]
20. Recent progress in combination therapy of oncolytic vaccinia virus.
Mirbahari SN; Da Silva M; Zúñiga AIM; Kooshki Zamani N; St-Laurent G; Totonchi M; Azad T
Front Immunol; 2024; 15():1272351. PubMed ID: 38558795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
